Since AML is a malignancy of myeloid lineage, we hypothesize that the aberrant CSF1R expression could be a putative leukemogenic driver in certain subsets of AML patients, e.g. inv (16) AML, which can be targeted by CSF1Ri. The gene discussed is CSF1R; the disease is acute myeloid leukemia.